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Sepsis is a complex biphasic syndrome characterized by both pro- and anti-inflammatory 
immune states. Whereas early sepsis mortality is caused by an acute, deleterious 
pro-inflammatory response, the second sepsis phase is governed by acute immuno-
suppression, which predisposes patients to long-term risk for life-threatening secondary 
infections. Despite extensive basic research and clinical trials, there is to date no specific 
therapy for sepsis, and mortality rates are on the rise. Although IFN-β is one of the 
most-studied cytokines, its diverse effects are not fully understood. Depending on the 
disease or type of infection, it can have beneficial or detrimental effects. As IFN-β has 
been used successfully to treat diverse diseases, emphasis has been placed on under-
standing the role of IFN-β in sepsis. Analyses of mouse models of septic shock attribute 
a pro-inflammatory role to IFN-β in sepsis development. As anti-inflammatory treatments 
in humans with antibodies to TNF-α or IL1-β resulted disappointing, cytokine modulation 
approaches were discouraged and neutralization of IFN-β has not been pursued for 
sepsis treatment. In the case of patients with delayed sepsis and immunosuppres-
sion, there is a debate as to whether the use of specific cytokines would restore the 
deactivated immune response. Recent reports show an association of low IFN-β levels 
with the hyporesponsive state of monocytes from sepsis patients and after endotoxin 
tolerance induction. These data, discussed here, project a role for IFN-β in restoring 
monocyte function and reversing immunosuppression, and suggest IFN-β-based addi-
tive immunomodulatory therapy. The dichotomy in putative therapeutic approaches, 
involving reduction or an increase in IFN-β levels, mirrors the contrasting nature of the 
early hyperinflammatory state and the delayed immunosuppression phase.
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inTRODUCTiOn
Sepsis is a systemic inflammatory syndrome caused by massive microbial infections and is a major 
cause of death worldwide. Sepsis is defined as an “organ dysfunction caused by a dysregulated host 
response to infection,” while septic shock is associated to a greater mortality risk, caused by “underly-
ing circulatory, cellular and metabolic abnormalities” (1, 2). Although survival of sepsis patients with 
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overwhelming pro-inflammatory responses is greatly improved 
in intensive care units (ICU), most patients develop delayed 
sepsis with severely suppressed immune responses and succumb 
to secondary infections (3, 4).
IFN-β is an essential cytokine in promoting and regulat-
ing innate and adaptive immune responses; its potential as 
an antimicrobial agent has been studied extensively. Data 
from murine models have assigned IFN-β a role in septic 
shock development, and its neutralization is proposed as a 
therapeutic strategy for human sepsis (5). As recent findings 
show low IFN-β expression by non-responsive monocytes in 
delayed sepsis patients, we discuss the therapeutic value of 
blocking or enhancing the levels of this cytokine to modulate 
immunosuppression.
Sepsis Progression from 
Hyperinflammation and early Death to 
immunosuppression and Delayed Death
Following massive microbial infection, highly produced inflam-
matory cytokines, mainly TNF-α and IL-1β, drive hyperinflam-
mation in sepsis patients (6, 7). Patients can suffer early death 
several days after systemic infection, due to sepsis and septic 
shock (8). Improvement in ICU care and compliance with the 
“Surviving Sepsis Campaign,” which provides clinical practice 
guidelines for the recognition and management of sepsis and 
septic shock, has reduced death incidence of sepsis patients 
(9–11). Early sepsis patients that survive ICU can nonetheless 
develop delayed sepsis and immunosuppression (12, 13). Patient 
death can be prolonged after initial sepsis diagnosis, due to a 
deactivated immune response (14, 15).
Hyporesponsiveness is considered a counteracting mecha-
nism that regulates hyperinflammation and alleviates the 
deleterious effects of primary infection (16, 17). This state 
correlates with sepsis progression and death, as it is associated 
with increased risk for secondary nosocomial infections (3). 
In a recent review, Delano and Ward (18) present the evolu-
tion of mortality as early and late deaths and introduce a third 
modality of sepsis, long-term death, which can be delayed for 
years. As the incidence of early deaths in the ICU has dimin-
ished over the years (4), the burden of sepsis-related deaths is 
linked to the hyporesponsive phase of the syndrome, and late 
and long-term deaths are on the rise (19). The progression from 
initial sepsis to the prolonged syndrome is not clearly defined 
and the host response to sepsis might consist of concurrent 
inflammatory and immunosuppression processes (8, 20). Patients 
were recently identified that develop persistent inflammation-
immunosuppression and catabolism syndrome (PICS), which 
leads to ongoing organ injury and death (13, 18, 21).
Mouse Models for Analysis of the Biphasic 
Aspects of Sepsis
Mouse models are valuable tools with which to dissect the 
mechanisms of human disease, and aid in discovering innovative 
therapeutic advances. In sepsis, there is nonetheless a disparity 
at the molecular level between mouse models and the human 
syndrome (22–25), and human and mouse inflammatory diseases 
show low gene correlation (26). Findings from these models must 
thus be evaluated critically for applicability to human sepsis.
Injection of lipopolysaccharide (LPS, also termed endotoxin), 
a constituent of Gram-negative bacteria, leads to septic shock 
in mice. Infection models or cecal ligation and puncture (CLP) 
(27) also lead to septic shock. Compared to the widely used 
LPS model, the CLP model is a more clear approximation of 
polymicrobial sepsis as it leads to bacteremia, a feature shared 
with human sepsis (27).
Mouse systems that emulate hyporesponsiveness and delayed 
sepsis in humans are limited due to the inherent complexity of 
sepsis and to its heterogeneity. Non-lethal CLP models adapted 
to restrict death of treated mice can also be used to study delayed 
sepsis [see review by Dejager et al. (27)]. Mice subjected to mild 
CLP induction or CLP models treated with antibiotics survive 
early hyperinflammation and show long-term immune dysfunc-
tion. Exposure of these mice to secondary bacterial infection 
establishes the “two-hit” model that allows the study of compro-
mised responses (28).
Endotoxin tolerance is a convenient model for analysis of 
macrophage hyporesponsiveness; it is induced after exposure 
of mice to a non-lethal LPS dose that induces hyperinflamma-
tion (29, 30). In a few hours, macrophages from treated mice 
undergo functional reprogramming from activated M1 status to 
an M2 hyporesponsive phenotype, and epigenetic modifications 
could explain this polarization (31–34). Endotoxin-tolerant 
macrophages are hyporesponsive to subsequent LPS challenge, 
and produce low amounts of TNF-α, IFN-β, and inducible nitric 
oxide synthase (iNOS) (34). This system deviates from the CLP 
model and from basic human sepsis features, as it is limited to 
the effects of LPS and not bacterial infection, and the initial LPS 
treatment does not lead to trauma and death.
As in  vitro LPS stimulation induces endotoxin tolerance in 
human monocytes (31, 35) and their refractory state shows a cer-
tain analogy to monocyte hyporesponsiveness in sepsis patients 
(6, 15, 20), data from this model may be useful, but are considered 
preliminary (16, 24) and should be verified in CPL models and 
in human sepsis.
TReATMenT STRATeGieS  
FOR SePSiS: PAST AnD PReSenT
To date, intense research in the field has provided effective 
approaches for early sepsis treatment that have increased survival 
in the ICU (3, 21); there have nonetheless been no therapeutic 
advances for long-term sepsis-related immunosuppression.
To minimize the pro-inflammatory condition of sepsis patients, 
it seemed logical to antagonize hyperinflammation and to treat sepsis 
by neutralizing hyperinflammation through anti-TNF-α or -IL- 
1β specific antibodies (7). In mice, anti-TNF-α delivery protected 
from septic shock when delivered before or simultaneously 
with LPS, although patients treated with anti-TNF-α or -IL-1β 
antibodies failed to show sepsis improvement (7, 36). Perhaps, 
therapeutics directed to the early physio-pathological conditions 
that derive from this initial pro-inflammatory response would be 
more efficient in preventing early death in sepsis patients. One 
such condition is the activation of procoagulant pathways (27).
TABle 1 | Role of iFn-β in modulating hyperinflammatory and immunosuppressive responses in mouse models and humans.
Models of iFn-β in sepsis Reference
Hyperinflammation IFN-β and IFN-α/β receptor (IFNAR) deficiency protect mice from LPS-induced septic shock (73, 74)
IFN-β and IFNAR deficiency protect mice from TNF-α-induced lethal shock (75)
IFNAR blockade protects mice in cecal ligation and puncture model (76)
IFN-α protects from LPS-induced lethality in mice (77)
IFN-β protects from LPS-induced septic shock in mice (78)
LPS treatment induces IFN-β expression in human monocytes (31, 83)
Pseudomonas aeruginosa infection induces IFN-β expression in human whole blood (76)
Immunosuppression IFN-β stimulation increases inflammatory response during endotoxin tolerance (83)
IFN-β is downregulated during endotoxin tolerance (34, 83)
IFNAR deficiency increases lethality in mouse model of delayed sepsis (96)
IFN-β is downregulated in immunosuppressed monocytes from sepsis patients (83)
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The ideal treatment would be based on an approach that 
could remedy both phases of sepsis (37). Because of the con-
trasting nature of early and delayed sepsis, distinct therapeutic 
approaches are currently considered to control hyperinflamma-
tion or immunosuppression. Before treatment, the state of each 
patient should thus be taken into strict account and tested, for 
example, by measuring HLA-DR expression in myeloid cells and 
evaluating overall immune cell status (3, 18).
As early sepsis survivors eventually develop immunosuppres-
sion, there is particular interest in establishing interventions for 
the late sepsis phase and a debate as to whether treatment for 
such patients should focus on boosting the pro-inflammatory 
response (7, 37). Macrophages are directly associated with sepsis 
development since Gram-negative bacteria, major constituents of 
infection, promote their activation through the TLR4 receptor; 
macrophages can then acquire a deactivated status (16). Other 
immune components participate in immunosuppression devel-
opment in delayed sepsis. For example, T cell numbers decline 
due to apoptosis and attain an exhaustion state or impaired 
function, whereas T  regulatory cells (Treg) are associated with 
mortality of delayed sepsis patients. NK cells and neutrophils have 
altered signaling functions. Moreover, a population of immature 
myeloid-derived suppressor cells (MDSC) arises and promotes 
immunosuppression (8, 18, 21). Dendritic cells undergo apoptosis 
in sepsis (38–41) and subsequently reemerge, but their activity is 
compromised due to the production of anti-inflammatory IL-10 
(42–45). Because of these diverse immunosuppression features, it 
was suggested that intervention should not be limited to target-
ing a single affected immune component, but rather implement 
combination approaches to improve critical immune defects 
of sepsis-affected individuals (18). Such methods would imply 
delivery of immune modulators such as G-CSF, GM-CSF, IFN-γ, 
or IL-15 (7, 18), to reconstitute specific immune deficiencies that 
depend on sepsis stage and the patient’s needs.
THe ROle OF iFn-β in iMMUne  
DiSeASe AnD in SePSiS
iFn-β in infection and Disease: Beneficial 
and Harmful effects
The interferons are cytokines that modulate the immune 
response and antimicrobial infection; they are classified as types 
I, II, and III. IFN-γ is the only type-II cytokine, and IFN-α and -β 
(IFNα/β) of the broad IFN I family are the most studied. After 
microbial infection, endothelial, epithelial, and immune cells 
detect through their pattern-recognition receptors (PRRs), 
which include TLR, pathogen-associated molecular patterns 
(PAMPs). This interaction promotes IFN-β, which is pro-
duced by most nucleated cells (46, 47). All type-I IFNs bind 
to the same cell surface IFN-α/β receptor (IFNAR). Signaling 
through IFNAR initiates a cascade of events, which activates 
innate cells, and elicits chemokine/cytokine production and 
activation of adaptive immunity (47). IFNα/β was initially 
found to have antiviral activity, as their defective signaling 
increases viral susceptibility (48–53). Accordingly, IFN-α is 
effective for treatment of viral infections such as hepatitis C 
(54), and IFN-β is also used in cancer treatment (55). IFNα/β 
can nonetheless have detrimental immunosuppressive effects 
during chronic infection with certain viruses (56, 57). These 
contrasting roles of IFNα/β in controlling or exacerbating 
disease are a central feature of these pleiotropic cytokines 
(58). Similarly, IFNα/β might contribute to the development 
of autoimmune diseases such as lupus or psoriasis (59–61), 
whereas IFN-β can be beneficial in a large proportion of 
multiple sclerosis patients (62). In another setting, although 
IFNα/β are critical in the defense against bacteria (63–67), 
they could also impede antibacterial immunity by inducing 
apoptosis of immune cells, by suppressing inflammatory 
cytokine release, by responsiveness to IFN-γ, or by promoting 
IL-10 production (68–71).
In general terms, IFNα/β boosts pro-inflammatory cytokine/
chemokine production and activates adaptive immunity, but 
also has diverse roles in immunity and, depending on context, 
might also suppress immune responses. IFN-α and IFN-β share a 
common receptor with apparently redundant functions. The two 
cytokines are used differently for treatment, and IFN-α is highly 
produced by plasmacytoid dendritic cells (47). The differences 
between IFN-α and IFN-β probably derive from the weak IFN-α 
binding to their common receptor (72).
iFn-β neutralization in Treating 
Hyperinflammation in Acute Sepsis
Several studies in IFN-β- and IFNAR-deficient mouse models of 
LPS- or TNF-α-induced septic shock suggest a pro-inflammatory 
FiGURe 1 | Role of iFn-β in hyperactivated and hyporesponsive monocytes/macrophages. Left, hyperactivated macrophages or monocytes present 
hyperinflammatory status and elevated IFN-β production. Secreted IFN-β interacts with its receptor and propagates the immune responses through iNOS and 
chemokine production. Neutralization of the IFN-β pathway interrupts these responses and could be beneficial in sepsis treatment. Right, hyporesponsive 
macrophages or monocytes associated with delayed sepsis or endotoxin tolerance arise from their hyperactivated counterparts, as a result of immunosuppression, 
driven by p21. TLR4 restimulation of such cells shows compromised activation pathways and inflammatory cytokine production, including IFN-β. IFN-β treatment 
could restore compromised monocyte functions and benefit immunosuppressed delayed sepsis patients.
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role for IFN-β in septic shock (Table 1) (73–75). These observa-
tions support the idea of IFN-β or IFNAR neutralization as an 
adjunctive immunomodulatory therapy for sepsis (5). This 
view was corroborated by a subsequent report showing that 
IFNAR is needed for CLP-triggered sepsis development (76). 
An anti-IFNAR antibody also reduced sepsis symptoms and was 
functional even when injected after CLP induction, thus reinforc-
ing the potential of IFN-β signaling inactivation as a therapeutic 
approach for sepsis (76). Sepsis improvement by the anti-IFNAR 
antibody precludes doubts about the relevance of data from mice 
in which IFN signaling is genetically abolished, based on the 
supposition that knockout mice might not reproduce the exact 
function of the eliminated gene. Studies in which septic shock 
was reduced by IFN-α (77) or IFN-β delivery (78) that suggest an 
anti-inflammatory effect for these cytokines need to be reinter-
preted. Perhaps, the injected cytokine dose in these two studies 
elicits non-physiological effects that increase survival, as there is 
a striking difference between physiological IFN-β levels and those 
used for treatment (79). The role of IFN-β appears to lie more in 
propagating the inflammatory response than in initiating it, as 
its effect differs from that of TNF-α, a potent pro-inflammatory 
agent that causes septic shock in mice (75). In accordance with 
this view, TNF-α induces IFN-β production (58).
TLR4 stimulation elicits hyperinflammation and IFN-β  
signaling in monocytes and macrophages as illustrated in 
Figure  1 (left). TLR4 triggering recruits MyD88 (myeloid dif-
ferentiation primary-response protein 88) in order to activate 
both NF-κB and protein kinases (MAPK), which drives nuclear 
translocation of p65/p50 NF-κB and phospho-AP-1 and tran-
scription of inflammatory cytokines. TLR4 stimulation also 
results in phosphorylation of IFN-regulatory factor 3 (IRF3), 
which in conjunction with NF-κB, induces expression of IFN-β 
(80, 81). Secretion of IFN-β activates the IFNAR complex in an 
autocrine manner. Subsequent STAT1 phosphorylation induces 
IFN-responsive elements such as iNOS, and chemokines such 
as CXCL9, CXCL10, and CXCL11 (Figure 1), which are potent 
white blood cell (WBC) attractors that further potentiate the 
immune response (31, 32, 82).
We recently showed that neutralization of IFNAR reduces 
iNOS and NO production as well as WBC-attracting 
chemokines in a mouse model of increased response to LPS 
(83). Neutralization of IFN-β signaling could thus reduce the 
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propagation of inflammation and harmful physiological effects 
that depend on persistent NO production (83). These findings 
corroborate the idea that IFN-β does not act as an immediate 
hyperinflammatory factor, and its neutralization could be an 
attractive option that allows a greater margin for intervention, as 
the interval of hyperinflammation induction might be too short 
for effective treatment.
These data reinforce the idea that neutralizing IFN-β signaling 
could be a therapeutic option for acute sepsis patients. As sug-
gested by Mahiou et al. (5), such an approach might be applied 
to relieve acute hyperinflammation, and caution should be taken 
to exclude patients with delayed sepsis to avoid aggravated 
immunosuppression.
iFn-β in Restoring Functions of 
Compromised immune Components
Boosting monocytes and other immune components to recover 
function is a prospective therapeutic approach for immunocom-
promised late sepsis patients. This idea is based on data showing 
that immunosuppressed monocytes from late sepsis patients 
recover HLA-DR levels and inflammation modulators after IFN-
γ treatment (84). Although IFN-γ delivery to trauma or sepsis 
patients in clinical studies had some positive effects, it does not 
cure sepsis (7, 18). It is therefore suggested that a combination of 
IFN-γ treatment with GM-CSF, another monocyte booster, might 
prove more effective in treating immunosuppression in sepsis (7). 
The prevailing idea is that key cytokines or other pharmacological 
agents could revert immunosuppression of monocytes and other 
immune cells (37). Here we evaluate whether IFN-β could be 
included in the chart of promising factors to alleviate immuno-
suppression (7, 18).
IFN-β is essential for human monocyte inflammation (31), 
but is downmodulated in endotoxin-tolerized monocytes 
(34, 83). Importantly, IFN-β is also downregulated in immu-
nosuppressed monocytes from sepsis patients (Table  1) (83), 
which implies that IFN-β downregulation could be critical for 
immunosuppression of monocytes in human sepsis, and that 
IFN-β treatment could reverse monocyte deactivation.
p21 was initially identified as a cell cycle and cyclin-dependent 
kinase 2 inhibitor (CDK2) (85). Other functions have been 
attributed to p21 (86, 87), and several studies designate it as an 
immune response modulator. p21 inhibits development of auto-
reactive T cells and autoimmunity (88–91). Moreover, it controls 
macrophage activation in septic shock and rheumatoid arthritis 
(92–94) and inhibits LPS-induced NF-κB activation, as well as 
endotoxin hyporesponsiveness of macrophages and monocytes 
(83). p21 regulates IFN-β levels in human monocytes, and mono-
cytes from sepsis patients show high p21 levels, which correlate 
with low IFN-β expression.
These data suggest a model in which monocyte immunosup-
pression is controlled by p21, which promotes inhibitory p50–
p50 over active p65–p50 NF-κB products (Figure 1, right). This 
p21 effect compromises production of inflammatory cytokines 
and IFN-β, and reduces iNOS induction and chemokine 
upregulation, which impairs WBC attraction and activation 
of innate and adaptive immunity (34, 47, 55, 83, 95). These 
IFNAR-dependent effects could theoretically be reestablished 
by an exogenous supply of IFN-β and thus restore monocyte 
functions and counteract immunosuppression (Figure 1, right). 
This model is further reinforced by our recent work showing that 
IFN-β treatment of endotoxin hyporesponsive macrophages 
increases expression of iNOS and CXCL11 (83). IFN-β can thus 
reestablish critical functional properties in immunosuppressed 
monocytes.
The role of IFN-β in controlling infection in long-term sepsis 
is supported by a mild CLP sepsis model. In such settings, WT 
mice survive the initial inflammatory shock, control bacteremia, 
and elude delayed death, whereas IFN-β-deficient mice, also 
unaffected by early inflammation, succumb to infection, and 
undergo late death (96). The data from this model, which in a way 
resembles delayed sepsis, show association of IFN-β expression 
with production of CXCL10, a chemokine that promotes hom-
ing of immune cells such as neutrophils (95,  96). In this mild 
CLP model, immunosuppression is possibly partial and IFN-β 
is produced. The results, however, support our view (Figure 1, 
right) that IFN-β, which must be supplied exogenously in severe 
immunosuppression, is essential for chemokine-mediated WBC 
attraction and antimicrobial action.
The model in Figure  1 (right) shows the possible effect of 
exogenous IFN-β in reversing monocyte hyporesponsiveness. 
This IFN-β effect can be extended to other immunosuppressed 
immune cells, as it can increase effector T  cells, antibody 
responses in B  cells, and activate innate immunity and anti-
gen presentation (47, 95). As IFN-β can induce dendritic cell 
maturation (95), this cytokine could enhance the generation 
of dendritic cells, which are reduced by apoptosis in sepsis 
patients. Similarly to monocytes, exogenous IFN-β could 
reverse immunosuppressive aspects of dendritic cells, includ-
ing IL-10 production, which inhibits IL-12 synthesis and T cell 
stimulation (45, 97).
Apart from its activating effect in monocytes and consistent 
with its pleiotropic antimicrobial responses, IFN-β could thus 
abrogate a wide range of sepsis-associated immunosuppressive 
responses. As little is known about its positive immunomodula-
tory effects in sepsis, establishing a role for IFN-β in antagonizing 
immunosuppression requires experimental evidence. Testing the 
effect of exogenous IFN-β in the “two hit” mouse model (28) 
could impart some early answers on its suitability for treatment 
of sepsis, which should be evaluated in human sepsis.
IFN-β has adverse immune effects that hinder microbial clear-
ance in some systems (47, 98), such as proapoptotic effects on 
innate cells and T cells, inhibition of the IFN-γ pathway in mac-
rophages, as well as generation of IL-10-producing Treg cells (58). 
The idea that IFN-β delivery might benefit immunosuppressed 
patients with delayed sepsis thus needs to be assessed meticu-
lously. As the negative immune impact of IFN-β in infection is 
manifested in the context of certain but not all microbial infec-
tions, sepsis treatment might not be affected by these discordant 
IFN-β effects.
Much experimentation remains in order to elucidate the 
potential immunomodulatory effect of IFN-β in sepsis thera-
peutics and to estimate whether, in addition to IFN-β, any other 
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stimulus could aid in efficient immune response reactivation in 
patients with delayed sepsis.
COnClUDinG ReMARKS
The failure of anti-TNF-α- or IL-1β-based therapies to decrease 
the death toll in sepsis patients has generated doubts as to 
whether cytokine-based treatments can be effective. Recent 
research has given new impetus to the field, and appropriate 
cytokine combinations are being considered for restoring 
suppressed immune functions in delayed sepsis patients. IFN-
β-based therapeutic approaches such as neutralization could 
be used during the hyperinflammation phase of sepsis, but also 
during the immunosuppression phase, with IFN-β delivery 
to boost suppressed immunity. A thorough analysis of indi-
vidual sepsis patients is needed before applying such radically 
opposed treatments for hyperinflammation or hyporesponsive-
ness. Patients with established immunosuppression might thus 
be a clearer target for IFN-β treatment to refurbish immune 
responses. Research is needed in mouse models and in humans 
to determine the precise mechanistic aspects and effectiveness 
of IFN-β-based treatments.
AUTHOR COnTRiBUTiOnS
GR composed the figures and contributed in writing the 
manuscript; RS composed the final versions of the figures and 
organised the argument and the manuscript; MM and CM-A 
contributed to the intellectual content of the manuscript. DB 
conceived and wrote the manuscript; all authors read and 
approved the final version of the manuscript.
ACKnOwleDGMenTS 
We thank C. Mark for editorial assistance.
FUnDinG
GR was funded by a predoctoral fellowship from the “La Caixa” 
program. This work was supported by grants from the Ministry of 
Economy and Competitivity (MINECO/FEDER PI11/00950 and 
SAF2016-80803-R to DB, and SAF2013-42289-R and SAF2016-
75456-R to CM-A), from the Fundación Alfonso Martin Escudero 
to CM-A, and from the Community of Madrid (MITIC S2011/
BMD2502 to DB, MM, and CM-A).
ReFeRenCeS
1. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. 
Assessment of clinical criteria for sepsis: for the third international consensus 
definitions for sepsis and septic shock (sepsis-3). JAMA (2016) 315:762–74. 
doi:10.1001/jama.2016.0288 
2. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, 
Deutschman CS, et al. Developing a new definition and assessing new clinical 
criteria for septic shock. JAMA (2016) 315:775. doi:10.1001/jama.2016.0289 
3. Angus D, van der Poll T. Severe sepsis and septic shock. N Engl J Med (2013) 
369:840–51. doi:10.1056/NEJMra1208623 
4. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. 
Immunity (2014) 40:463–75. doi:10.1016/j.immuni.2014.04.001 
5. Mahieu T, Libert C. Should we inhibit type I interferons in sepsis? Infect 
Immun (2007) 75:22–9. doi:10.1128/IAI.00829-06 
6. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tol-
erance as a model of leukocyte reprogramming in sepsis. Crit Care (2006) 
10:233. doi:10.1186/cc5055 
7. Brown KA, Brown GA, Lewis SM, Beale R, Treacher DF. Targeting cytokines as 
a treatment for patients with sepsis: a lost cause or a strategy still worthy of pur-
suit? Int Immunopharmacol (2016) 36:291–9. doi:10.1016/j.intimp.2016.04.041 
8. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: 
from cellular dysfunctions to immunotherapy. Nat Rev Immunol (2013) 
13:862–74. doi:10.1038/nri3552 
9. Castellanos-Ortega A, Suberviola B, Garcia-Astudillo LA, Holanda MS, Ortiz F, 
Llorca J, et al. Impact of the Surviving Sepsis Campaign protocols on hos-
pital length of stay and mortality in septic shock patients: results of a three-
year follow-up quasi-experimental study. Crit Care Med (2010) 38:1036–43. 
doi:10.1097/CCM.0b013e3181d455b6 
10. Delano MJ, Ward PA. The immune system’s role in sepsis progression, resolu-
tion, and long-term outcome. Immunol Rev (2016) 274:330–53. doi:10.1111/
imr.12499 
11. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. 
Surviving sepsis campaign: international guidelines for management of sepsis 
and septic shock: 2016. Crit Care Med (2017) 45(3):486–552. doi:10.1097/
CCM.0000000000002255 
12. Adib-Conquy M, Cavaillon J-M. Compensatory anti-inflammatory response 
syndrome. Thromb Haemost (2009) 101(1):36–47. doi:10.1160/TH08-07-0421 
13. Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, et  al. 
Persistent inflammation and immunosuppression: a common syndrome and 
new horizon for surgical intensive care. J Trauma Acute Care Surg (2012) 
72:1491–501. doi:10.1097/TA.0b013e318256e000.Persistent 
14. Escoll P, del Fresno C, García L, Vallés G, Lendínez MJ, Arnalich F, et al. 
Rapid up-regulation of IRAK-M expression following a second endotoxin 
challenge in human monocytes and in monocytes isolated from septic 
patients. Biochem Biophys Res Commun (2003) 311:465–72. doi:10.1016/j.
bbrc.2003.10.019 
15. Shalova IN, Lim JY, Chittezhath M, Zinkernagel AS, Beasley F, Hernández-
Jiménez E, et  al. Human monocytes undergo functional re-programming 
during sepsis mediated by hypoxia-inducible factor-1α. Immunity (2015) 
42:484–98. doi:10.1016/j.immuni.2015.02.001 
16. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, 
molecules and clinical significance. Trends Immunol (2009) 30:475–87. 
doi:10.1016/j.it.2009.07.009 
17. López-Collazo E, Del Fresno C. Pathophysiology of endotoxin tolerance: 
mechanisms and clinical consequences. Crit Care (2013) 17:242. doi:10.1186/
cc13110 
18. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune ther-
apies reduce mortality? J Clin Invest (2016) 126:23–31. doi:10.1172/JCI82224 
19. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE. 
Long-term mortality and quality of life in sepsis: a systematic review. Crit Care 
Med (2010) 38:1276–83. doi:10.1097/CCM.0b013e3181d8cc1d 
20. Pena OM, Hancock DG, Lyle NH, Linder A, Russell JA, Xia J, et  al. An 
endotoxin tolerance signature predicts sepsis and organ dysfunction at 
initial clinical presentation. EBioMedicine (2014) 1:64–71. doi:10.1016/j.
ebiom.2014.10.003.An 
21. Rosenthal MD, Moore FA. Persistent inflammation, immunosuppression, and 
catabolism: evolution of multiple organ dysfunction. Surg Infect (Larchmt) 
(2016) 17:167–72. doi:10.1089/sur.2015.184 
22. Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G. LPS-induced upregula-
tion of SHIP is essential for endotoxin tolerance. Immunity (2004) 21:227–39. 
doi:10.1016/j.immuni.2004.07.010 
23. Liew FY, Xu D, Brint EK, O’Neill LAJ. Negative regulation of toll-like 
receptor-mediated immune responses. Nat Rev Immunol (2005) 5:446–58. 
doi:10.1038/nri1630 
24. Del Fresno C, García-Rio F, Gómez-Piña V, Soares-Schanoski A, 
Fernández-Ruíz I, Jurado T, et al. Potent phagocytic activity with impaired 
antigen presentation identifying lipopolysaccharide-tolerant human mono-
cytes: demonstration in isolated monocytes from cystic fibrosis patients. 
J Immunol (2009) 182:6494–507. doi:10.4049/jimmunol.0803350 
7Rackov et al. Role of IFN-β in Sepsis
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 493
25. van ’t Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, 
Stroes ES, et al. Induction of IRAK-M is associated with lipopolysaccharide 
tolerance in a human endotoxemia model. J Immunol (2007) 179:7110–20. 
doi:10.4049/jimmunol.179.10.7110 
26. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic 
responses in mouse models poorly mimic human inflammatory diseases. Proc 
Natl Acad Sci U S A (2013) 110:3507–12. doi:10.1073/pnas.1222878110 
27. Dejager L, Pinheiro I, Dejonckheere E, Libert C. Cecal ligation and puncture: 
the gold standard model for polymicrobial sepsis? Trends Microbiol (2011) 
19:198–208. doi:10.1016/j.tim.2011.01.001 
28. Nascimento DC, Alves-Filho JC, Sonego F, Fukada SY, Pereira MS, Benjamim C, 
et al. Role of regulatory T cells in long-term immune dysfunction associated 
with severe sepsis. Crit Care Med (2010) 38:1718–25. doi:10.1097/CCM. 
0b013e3181e78ad0 
29. Berg DJ, Kühn R, Rajewsky K, Müller W, Menon S, Davidson N, et  al. 
Interleukin-10 is a central regulator of the response to LPS in murine models 
of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. 
J Clin Invest (1995) 96:2339–47. doi:10.1172/JCI118290 
30. Wysocka M, Robertson S, Riemann H, Caamano J, Hunter C, Mackiewicz A, 
et al. IL-12 suppression during experimental endotoxin tolerance: dendritic 
cell loss and macrophage hyporesponsiveness. J Immunol (2001) 166:7504–13. 
doi:10.4049/jimmunol.166.12.7504 
31. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, et al. Tolerance and 
M2 (alternative) macrophage polarization are related processes orchestrated 
by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A (2009) 106:14978–83. 
doi:10.1073/pnas.0809784106 
32. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. 
J Clin Invest (2012) 122:787–95. doi:10.1172/JCI59643DS1 
33. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflam-
mation by TLR-induced chromatin modifications. Nature (2007) 447:972–8. 
doi:10.1038/nature05836 
34. Piao W, Song C, Chen H, Diaz MA, Wahl LM, Fitzgerald KA, et al. Endotoxin 
tolerance dysregulates MyD88- and toll/IL-1R domain-containing adapter 
inducing IFN-beta-dependent pathways and increases expression of negative 
regulators of TLR signaling. J Leukoc Biol (2009) 86:863–75. doi:10.1189/
jlb.0309189 
35. Pena OM, Pistolic J, Raj D, Fjell CD, Hancock RE. Endotoxin tolerance 
represents a distinctive state of alternative polarization (M2) in human mono-
nuclear cells. J Immunol (2011) 186:7243–54. doi:10.4049/jimmunol.1001952 
36. Lyle NH, Pena OM, Boyd JH, Hancock RE. Barriers to the effective treatment 
of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies. 
Ann N Y Acad Sci (2014) 1323:101–14. doi:10.1111/nyas.12444 
37. Cavaillon JM, Eisen D, Annane D. Is boosting the immune system in sepsis 
appropriate? Crit Care (2014) 18(2):216. doi:10.1186/cc13787 
38. Grimaldi D, Louis S, Pene F, Sirgo G, Rousseau C, Claessens YE, et  al. 
Profound and persistent decrease of circulating dendritic cells is associated 
with ICU-acquired infection in patients with septic shock. Intensive Care Med 
(2011) 37:1438–46. doi:10.1007/s00134-011-2306-1 
39. Guisset O, Dilhuydy MS, Thiebaut R, Lefevre J, Camou F, Sarrat A, et  al. 
Decrease in circulating dendritic cells predicts fatal outcome in septic shock. 
Intensive Care Med (2007) 33:148–52. doi:10.1007/s00134-006-0436-7 
40. Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF, 
Wagner TH, et  al. Depletion of dendritic cells, but not macrophages, 
in patients with sepsis. J Immunol (2002) 168:2493–500. doi:10.4049/
jimmunol.168.5.2493 
41. Efron PA, Martins A, Minnich D, Tinsley K, Ungaro R, Bahjat FR, et  al. 
Characterization of the systemic loss of dendritic cells in murine lymph nodes 
during polymicrobial sepsis. J Immunol (2004) 173:3035–43. doi:10.4049/
jimmunol.173.5.3035 
42. Riccardi F, Della Porta MG, Rovati B, Casazza A, Radolovich D, De Amici M, 
et al. Flow cytometric analysis of peripheral blood dendritic cells in patients 
with severe sepsis. Cytometry B Clin Cytom (2011) 80:14–21. doi:10.1002/
cyto.b.20540 
43. Poehlmann H, Schefold JC, Zuckermann-Becker H, Volk HD, Meisel C. 
Phenotype changes and impaired function of dendritic cell subsets in patients 
with sepsis: a prospective observational analysis. Crit Care (2009) 13:R119. 
doi:10.1186/cc7969 
44. Pastille E, Didovic S, Brauckmann D, Rani M, Agrawal H, Schade FU, et al. 
Modulation of dendritic cell differentiation in the bone marrow mediates 
sustained immunosuppression after polymicrobial sepsis. J Immunol (2011) 
186:977–86. doi:10.4049/jimmunol.1001147 
45. Fallarino F, Pallotta MT, Matino D, Gargaro M, Orabona C, Vacca C, et al. 
LPS-conditioned dendritic cells confer endotoxin tolerance contingent on 
tryptophan catabolism. Immunobiology (2015) 220:315–21. doi:10.1016/j.
imbio.2014.09.017 
46. Raymond SL, Holden DC, Mira JC, Stortz JA, Loftus TJ, Mohr AM, et  al. 
Microbial recognition and danger signals in sepsis and trauma. Biochim 
Biophys Acta (2017). doi:10.1016/j.bbadis.2017.01.013 
47. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev 
Immunol (2013) 14:36–49. doi:10.1038/nri3581 
48. Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, 
et al. Impaired response to interferon-alpha/beta and lethal viral disease 
in human STAT1 deficiency. Nat Genet (2003) 33:388–91. doi:10.1038/
ng1097 
49. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and 
STATs. Immunity (2012) 36:515–28. doi:10.1016/j.immuni.2012.03.016 
50. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, Hamilton JA, 
et al. A null mutation in the gene encoding a type I interferon receptor com-
ponent eliminates antiproliferative and antiviral responses to interferons alpha 
and beta and alters macrophage responses. Proc Natl Acad Sci U S A (1995) 
92:11284–8. doi:10.1073/pnas.92.24.11284 
51. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the 
master regulator of type-I interferon-dependent immune responses. Nature 
(2005) 434:772–7. doi:10.1038/nature03464 
52. Rudd PA, Wilson J, Gardner J, Larcher T, Babarit C, Le TT, et al. Interferon 
response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever 
and shock. J Virol (2012) 86:9888–98. doi:10.1128/JVI.00956-12 
53. Daffis S, Lazear HM, Liu WJ, Audsley M, Engle M, Khromykh AA, et  al. 
The naturally attenuated Kunjin strain of West Nile virus shows enhanced 
sensitivity to the host type I interferon response. J Virol (2011) 85:5664–8. 
doi:10.1128/JVI.00232-11 
54. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, 
Filipowicz W, et  al. Interferon signaling and treatment outcome in chronic 
hepatitis C. Proc Natl Acad Sci U S A (2008) 105:7034–9. doi:10.1073/pnas. 
0707882105 
55. González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions 
of type I interferons. Nat Rev Immunol (2012) 12:125–35. doi:10.1038/nri3133 
56. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, et al. Persistent 
LCMV infection is controlled by blockade of type I interferon signaling. 
Science (2013) 340:207–11. doi:10.1126/science.1235214 
57. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, et al. 
Blockade of chronic type I interferon signaling to control persistent LCMV 
infection. Science (2013) 340:202–7. doi:10.1126/science.1235208 
58. Trinchieri G. Type I interferon: friend or foe? J Exp Med (2010) 207:2053–63. 
doi:10.1084/jem.20101664 
59. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. 
Curr Opin Rheumatol (2013) 25:248–53. doi:10.1097/BOR.0b013e32835c7e32 
60. Baccala R, Gonzalez-Quintial R, Schreiber RD, Lawson BR, Kono DH, 
Theofilopoulos AN. Anti-IFN-α/β receptor antibody treatment amelio-
rates disease in lupus-predisposed mice. J Immunol (2012) 189:5976–84. 
doi:10.4049/jimmunol.1201477 
61. Grine L, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle 
in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev (2015) 
26:25–33. doi:10.1016/j.cytogfr.2014.10.009 
62. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung H-P. Immunopathogenesis 
and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol (2006) 
2:201–11. doi:10.1038/ncpneuro0154 
63. De la Maza LM, Peterson EM, Goebel JM, Fennie CW, Czarniecki CW. 
Interferon-induced inhibition of Chlamydia trachomatis: dissociation from 
antiviral and antiproliferative effects. Infect Immun (1985) 47:719–22. 
64. Rothfuchs AG, Gigliotti D, Palmblad K, Andersson U, Wigzell H, Rottenberg ME. 
IFN-alpha beta-dependent, IFN-gamma secretion by bone marrow-derived 
macrophages controls an intracellular bacterial infection. J Immunol (2001) 
167:6453–61. doi:10.4049/jimmunol.167.11.6453 
65. Rothfuchs AG, Trumstedt C, Mattei F, Schiavoni G, Hidmark A, Wigzell H, 
et al. STAT1 regulates IFN-alpha beta- and IFN-gamma-dependent control 
of infection with Chlamydia pneumoniae by nonhemopoietic cells. J Immunol 
(2006) 176:6982–90. doi:10.4049/jimmunol.176.11.6982 
8Rackov et al. Role of IFN-β in Sepsis
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 493
66. Mancuso G, Midiri A, Biondo C, Beninati C, Zummo S, Galbo R, et  al. 
Type I IFN signaling is crucial for host resistance against different species 
of pathogenic bacteria. J Immunol (2007) 178:3126–33. doi:10.4049/
jimmunol.178.5.3126 
67. Parker D, Martin FJ, Soong G, Harfenist BS, Aguilar JL, Ratner AJ, et  al. 
Streptococcus pneumoniae DNA initiates type I interferon signaling in the 
respiratory tract. MBio (2011) 2:e00016–11. doi:10.1128/mBio.00016-11 
68. Auerbuch V, Brockstedt DG, Meyer-Morse N, O’Riordan M, Portnoy DA. 
Mice lacking the type I interferon receptor are resistant to Listeria monocyto-
genes. J Exp Med (2004) 200:527–33. doi:10.1084/jem.20040976 
69. Carrero JA, Calderon B, Unanue ER. Type I interferon sensitizes lymphocytes 
to apoptosis and reduces resistance to Listeria infection. J Exp Med (2004) 
200:535–40. doi:10.1084/jem.20040769 
70. O’Connell RM, Saha SK, Vaidya SA, Bruhn KW, Miranda GA, Zarnegar B, 
et al. Type I interferon production enhances susceptibility to Listeria mono-
cytogenes infection. J Exp Med (2004) 200:437–45. doi:10.1084/jem.20040712 
71. McNab FW, Ewbank J, Howes A, Moreira-Teixeira L, Martirosyan A, Ghilardi N, 
et al. Type I IFN induces IL-10 production in an IL-27-independent manner 
and blocks responsiveness to IFN-gamma for production of IL-12 and bacte-
rial killing in Mycobacterium tuberculosis-infected macrophages. J Immunol 
(2014) 193:3600–12. doi:10.4049/jimmunol.1401088 
72. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, van der Heyden J, et al. 
Inquiring into the differential action of interferons (IFNs): an IFN-α2 mutant 
with enhanced affinity to IFNAR1 is functionally similar to IFN-β. Mol Cell 
Biol (2006) 26:1888–97. doi:10.1128/MCB.26.5.1888 
73. Karaghiosoff M, Steinborn R, Kovarik P, Kriegshäuser G, Baccarini M, 
Donabauer B, et al. Central role for type I interferons and Tyk2 in lipopolysac-
charide-induced endotoxin shock. Nat Immunol (2003) 4:471–7. doi:10.1038/
ni910 
74. Mahieu T, Park JM, Revets H, Pasche B, Lengeling A, Staelens J, et  al. The 
wild-derived inbred mouse strain SPRET/Ei is resistant to LPS and defec-
tive in IFN-beta production. Proc Natl Acad Sci U S A (2006) 103:2292–7. 
doi:10.1073/pnas.0510874103 
75. Huys L, Van Hauwermeiren F, Dejager L, Dejonckheere E, Lienenklaus S, 
Weiss S, et al. Type I interferon drives tumor necrosis factor-induced lethal 
shock. J Exp Med (2009) 206:1873–82. doi:10.1084/jem.20090213 
76. Dejager L, Vandevyver S, Ballegeer M, Van Wonterghem E, An L-L, Riggs J, 
et al. Pharmacological inhibition of type I interferon signaling protects mice 
against lethal sepsis. J Infect Dis (2013) 209:960–70. doi:10.1093/infdis/jit600 
77. Tzung SP, Mahl TC, Lance P, Andersen V, Cohen SA. Interferon-alpha prevents 
endotoxin-induced mortality in mice. Eur J Immunol (1992) 22:3097–101. 
doi:10.1002/eji.1830221211 
78. Yoo CH, Yeom JH, Heo JJ, Song EK, Lee SI, Han MK. Interferon β protects 
against lethal endotoxic and septic shock through SIRT1 upregulation. Sci Rep 
(2014) 4:4220. doi:10.1038/srep04220 
79. Berry CM. Understanding interferon subtype therapy for viral infections: 
harnessing the power of the innate immune system. Cytokine Growth Factor 
Rev (2016) 31:83–90. doi:10.1016/j.cytogfr.2016.08.001 
80. Kawai T, Akira S. Signaling to NF-kappaB by toll-like receptors. Trends Mol 
Med (2007) 13:460–9. doi:10.1016/j.molmed.2007.09.002 
81. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: 
update on toll-like receptors. Nat Immunol (2010) 11:373–84. doi:10.1038/
ni.1863 
82. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004) 
4:499–511. doi:10.1038/nri1391 
83. Rackov G, Hernández-Jiménez E, Shokri R, Carmona-Rodríguez L, Mañes S, 
Álvarez-Mon M, et  al. p21 mediates macrophage reprogramming through 
regulation of p50-p50 NF-κB and IFN-β. J Clin Invest (2016) 126:3089–103. 
doi:10.1172/JCI83404 
84. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et  al. 
Monocyte deactivation in septic patients: restoration by IFN-gamma treat-
ment. Nat Med (1997) 3:678–81. doi:10.1038/nm0697-678 
85. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-
interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. 
Cell (1993) 75:805–16. doi:10.1016/0092-8674(93)90499-G 
86. Lloberas J, Celada A. p21(waf1/CIP1), a CDK inhibitor and a negative 
feedback system that controls macrophage activation. Eur J Immunol (2009) 
39:691–4. doi:10.1002/eji.200939262 
87. Perkins ND. Not just a CDK inhibitor: regulation of transcription by 
p21(WAF1/CIP1/SDI1). Cell Cycle (2002) 1:35–7. doi:10.4161/cc.1.1.98 
88. Zhu B, Symonds AL, Martin JE, Kioussis D, Wraith DC, Li S, et  al. Early 
growth response gene 2 (Egr-2) controls the self-tolerance of T  cells and 
prevents the development of lupuslike autoimmune disease. J Exp Med (2008) 
205:2295–307. doi:10.1084/jem.20080187 
89. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, et al. CD4+ T cells from 
elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin 
Invest (2011) 121:1549–60. doi:10.1172/JCI44539 
90. Arias CF, Ballesteros-tato A, Isabel M, Martín-caballero J, Flores JM, Martı C, 
et  al. p21 controls proliferation of activated/memory T  cells and affects 
homeostasis and memory T cell responses. J Immunol (2007) 178(4):2296–306. 
doi:10.4049/jimmunol.178.4.2296 
91. Daszkiewicz L, Vázquez-Mateo C, Rackov G, Ballesteros-Tato A, Weber K, 
Madrigal-Avilés A, et al. Supplemental methods distinct p21 requirements for 
regulating normal and self-reactive T cells through IFN-γ production. Sci Rep 
(2015) 5:7691. doi:10.1038/srep07691 
92. Trakala M, Arias CF, García MI, Moreno-Ortiz MC, Tsilingiri K, Fernández PJ, 
et al. Regulation of macrophage activation and septic shock susceptibility via 
p21(WAF1/CIP1). Eur J Immunol (2009) 39:810–9. doi:10.1002/eji.200838676 
93. Scatizzi JC, Mavers M, Hutcheson J, Young B, Shi B, Pope RM, et al. The CDK 
domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated 
macrophages. Eur J Immunol (2009) 39:820–5. doi:10.1002/eji.200838683 
94. Mavers M, Cuda CM, Misharin AV, Gierut AK, Agrawal H, Weber E, et al. 
Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential 
for resolution of murine inflammatory arthritis. Arthritis Rheum (2012) 
64:141–52. doi:10.1002/art.33311 
95. Uematsu S, Akira S. Toll-like receptors and type I interferons. J Biol Chem 
(2007) 282:15319–23. doi:10.1074/jbc.R700009200 
96. Kelly-Scumpia KM, Scumpia PO, Delano MJ, Weinstein JS, Cuenca AG, 
Wynn JL, et al. Type I interferon signaling in hematopoietic cells is required 
for survival in mouse polymicrobial sepsis by regulating CXCL10. J Exp Med 
(2010) 207:319–26. doi:10.1084/jem.20091959 
97. Fan X, Liu Z, Jin H, Yan J, Liang HP. Alterations of dendritic cells in sepsis: 
featured role in immunoparalysis. Biomed Res Int (2015) 2015:903720. 
doi:10.1155/2015/903720 
98. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in 
infectious disease. Nat Rev Immunol (2015) 15:87–103. doi:10.1038/nri3787 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Rackov, Shokri, De Mon, Martínez-A. and Balomenos. This 
is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
